CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients ‘extract every drop of potential from the RBQM-driven interrogation of their own datasets’.
CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients ‘extract every drop of potential from the RBQM-driven interrogation of their own datasets’.
CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform King of Prussia,